Levetiracetam Tablet, Film Coated
Product Images NDC 72865-187

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 72865-187). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1000-mg (1000 mg)

This is a description of a medicine pack of Levetiracetam Tablets with a batch coding size of 35x40 mm. It has a manufacturing license number of 24/MD/TS/2016/F/G issued to XLcare Pharmaceuticals Inc. Each tablet contains 1000 mg of Levetiracetam USP, and it is recommended to dispense in a tight, light-resistant container with a child-resistant closure. The usual dosage is included in the package insert. The medication guide is available on the manufacturer's website. The pack was manufactured by Annora Pharma Pvt. Ltd. in Sangareddy, Telangana, India.*

FDA Label Image

250-mg (250 mg)

FDA Label Image

500-mg (500 mg)

This is the description: The text contains information related to pharmaceutical product called Levetiracetam, manufactured by XLCare Pharmaceuticals Inc. The package contains 120 film-coated tablets each of 500 mg strength, and each patient is required to receive an accompanying medication guide. The package insert provides information on storage conditions, recommended dosage, and pharmacist instructions. The box also includes a batch code area for labeling purposes, but the text is incomplete and not readable. The manufacturing license number is available, along with the contact information of the company.*

FDA Label Image

750-mg (750 mg)

This is a description of pharmaceutical tablets containing Levetiracetam USP 750 mg manufactured by XLCare Pharmaceuticals, Inc. The tablets come in a bottle containing 120 tablets and are meant for Rx only. Each tablet is film-coated and should be dispensed in a tight, light-resistant container with a child-resistant closure. The recommended dosage should be referred to from the package insert. More information can be found on the company's website, including a medication guide. The manufacturer, XLCare Pharmaceuticals, Inc., is based in Lawrenceville, GA, and the tablets were manufactured by Annora Pharma Pvt. Ltd. in Telangana, India.*

FDA Label Image

Fig-1 (Fig 1)

This is a graph showing the percentage of patients in a study who were administered a placebo vs. different doses of Levetiracetam per day (1000 mg and 3000 mg). The study had a total of 293 participants (95 received placebo, 97 received 1000 mg/day, and 101 received 3000 mg/day).*

FDA Label Image

Fig-2 (Fig 2)

This appears to be a chart showing the percentage of patients in different treatment groups. The treatment groups include a placebo group and two groups receiving two different doses of a medication called Levetiracetam. The number of patients in each group is also provided.*

FDA Label Image

Fig-3 (Fig 3)

FDA Label Image

Fig-4 (Fig 4)

The text represents a table showing the percentage of patients who may have taken Placebo or Levetiracetam drugs. The table has two columns labeled "Placebo (N=97)" and "Levetiracetam (N=101)" respectively. The rows of the table indicate the percentage of patients who may have taken the drugs with values ranging from 0% to 45%.*

FDA Label Image

Fig-5 (Fig 5)

This is a chart that shows the percentage of patients who took either a placebo or levetiracetam (a medication used to treat seizures) and the percentage of those patients who experienced a certain outcome. The chart displays the percentage of patients on the y-axis (ranging from 0-45%) and the two treatment options (placebo and levetiracetam) on the x-axis. The percentages displayed range from 0% to 19.6% for the placebo group and 0% to 43.1% for the levetiracetam group.*

FDA Label Image

Fig-6 (Fig 6)

This appears to be a chart showing the percentage of patients who experienced a certain outcome in a clinical trial involving a placebo group (N=84) and a group taking levetiracetam (N=79). However, without more context or information about what the outcome is, it is difficult to provide a more detailed description.*

FDA Label Image

Levestructure (Levestructure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.